Sorafenib and tetrakis (4-carboxyphenyl) porphyrin assembled nanoparticles for synergistic targeted chemotherapy and sonodynamic therapy of hepatocellular carcinoma

• Published in: Biomaterials science Vol. 12; no. 7; pp. 1864 - 187
• Main Authors: Chen, Yongzhi, Tan, Qiuxia, Tang, Yuanyu, Pang, E, Peng, Rui, Lan, Minhuan, Bai, Dousheng
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 26.03.2024
• Subjects: Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; Cell Line, Tumor; Chemotherapy; Folic acid; Humans; Kinases; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Nanoparticles; Penetration resistance; Porphyrins; Porphyrins - pharmacology; Porphyrins - therapeutic use; Side effects; Sorafenib; Tumors
• ISSN: 2047-4830; 2047-4849
• DOI: 10.1039/d3bm01994b

Hepatocellular carcinoma (HCC) is characterized by a high degree of malignancy and mortality. Sorafenib (SOR), a multi-kinase inhibitor, is clinically used in the treatment of HCC. However, SOR suffers from serious side effects and drug resistance. The development of novel therapeutic strategies for HCC therapy is urgently needed. Sonodynamic therapy (SDT) has unique advantages in treating deep tumors due to the merits of deep tissue penetration, low side effects, and the absence of drug resistance. Here, we developed multifunctional nanoparticles (NPs) termed SOR-TCPP@PEG-FA by assembling SOR, tetrakis (4-carboxyphenyl) porphyrin (TCPP), and folic acid (FA)-modified DSPE-PEG. The FA group enhances the tumor targeting capability of these NPs, while TCPP generates ROS under ultrasound (US) irradiation, which are toxic to tumor cells, and SOR with chemotherapeutic effects is released, thus realizing the synergistic SDT and chemotherapy of tumors. Hepatocellular carcinoma (HCC) is characterized by a high degree of malignancy and mortality.